successes were achieved in 95% of cases. Type B2/C lesions were treated in 63% of cases. Long-term follow-up showed a combined major adverse cardiac events rate (death, MI and target lesion revascularization (TLR)) of 11%. All cause mortality was noted in 5%, cardiac mortality in 1%, MI in 6% and stroke in 1%. Finally, TLR and target vessel revascularization were noted in 3% and 4% of cases respectively. The independent predictors of MACE were cancer (Odds Ratio (OR): 6.55 [2.64, 16.28]; p<0.001), respiratory disease (OR: 4.41 [1.68, 10.47]; p<0.001), postdilation (OR: 2.85 [1.19-6.80]; p¼ 0.018) and type C lesions (OR: 1.91 [1.02-3.56]; p¼ 0.042). Conclusions: In this real life cohort, the treatment of highly complex lesions with the Osiro Stent was associated with excellent long-term results. Further randomized trials are warranted to confirm these findings.
Background: Long term safety and efficacy of the Elixir DESyneÒ BD Novolimus Eluting Coronary Stent System (NECSS), a Co-Cr stent with a bioabsorbable polymer compared to the control Endeavor Zotarolimus Eluting Coronary Stent System is not known Methods: 149 patients were randomized 3:1, either to the Elixir DESyne BD Novolimus Eluting CSS loaded with 5mcg per mm of stent length of Novolimus, a sirolimus metabolite, eluted via a bioabsorbable polylactide-based polymer, or to the Endeavor Zotarolimus-eluting CSS (ZECSS) loaded with 10mcg per mm of stent length of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were analyzed for the primary endpoint of in-stent late lumen loss (LLL) assessed by qualitative coronary angiography (QCA) at 6 months. Moreover, all patients underwent evaluation for the secondary endpoints including the Deviceorientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization; clinically-indicated Target Vessel Revascularization (TVR), and stent thrombosis at 1, 6, 9, and 12 months and annually through 5 years. Lesions were also evaluated for angiographic endpoints at 6 months including: in-segment LLL, percent diameter stenosis, minimal lumen diameter post-procedure, and angiographic binary restenosis (ABR) (!50%). A subset of patients underwent intravascular ultrasound (IVUS) evaluation including percent (%) neointimal obstruction at 6 months. Results: The study met the primary endpoint demonstrating both non-inferiority and superiority of the DESyne BD compared to the control (0.12AE0.15 vs 0.67AE0.47, p<0.001), additionally, in-stent ABR was significantly lower for DESyne BD (0% vs 7.9%, p¼0.003). Excellent clinical results at 6 months were demonstrated for both devices (DoCE 2.7% vs. 3.2%, p¼ 1.00). Sustained low clinical event rates were observed at 12 months and 24 months (DoCE 2.7% vs 3.2% p¼1.0) Conclusions: The DESyne BD NECSS demonstrated sequential non-inferiority and superiority over a durable polymer Endeavor ZECSS for in-stent late lumen loss at 6 months. Clinical events remained low through 24 months suggesting long term safety.
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The middle-term outcome of small-vessel stenting with the second-generation drug-eluting stents. Background: The outcome of small-vessel stenting with the second-generation drugeluting stents (DES) remains uncertain. Stents deployed in small arteries, have a higher metal-to-artery ratio; this may increase the risk of restenosis. Specific attributes of stent design, including strut thickness and eluting drug, influence stent performance characteristics, particularly in smaller coronary vessels. Methods: This study is a single-center, retrospective observational study. From April 2009 to December 2011, 264 patients with small vessel coronary artery disease were treated with 2.5mm DES implantation, which consisted of 225 patients with 2.5mm Everolimus eluting stent (EES) implantation and 39 patients with 2.5mm Biolimus eluting stent (BES) implantation. Out of these patients, 226 patients underwent followup coronary angiography at eight months post-PCI. We evaluated the results of those 226 patients. Results: Though pre-PCI reference vessel diameter were less in EES group than BES group (EES:2.11AE0.34, BES:2.25AE0.28 mm, p<0.05), there were no significant difference in patient characteristics, pre-PCI minimal lumen diameter(MLD) (0.69AE0.36, 0.71AE0.41 mm) and angiographic percent diameter stenosis(PDS)(67.8AE17.1, 69.3AE18.7 %). Post-PCI MLD of BES group were smaller than those of EES group. (1.96AE0.31, 2.08AE0.31 mm p<0.05) Post-PCI PDS(11.0AE10.9, 8.3AE10.5 %) and acute gain(1.31AE0.46, 1.44AE0.47 mm) were similar in both groups. At follow-up coronary angiography eight months later, there were no significant difference in MLD(1.85AE0.55, 2.02AE0.59 mm), PDS(21.6AE20.7, 19.4AE17.1 %), binary restenosis (17 cases; 7.6%, 3 cases; 7.7%) and target lesion revacularization (7 cases; 3%, 0 case; 0%). Conclusions: Though pre-PCI lesion characteristics of BES group were a little better than those of EES group, there were no significant difference between EES and BES in the middle-term outcome of small-vessel stenting.
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Impact of Pioglitazone on Cardiovascular Events in Patients with Type-2 Diabetes Mellitus after Drug-eluting Stent Implantation
Hiroyoshi Yokoi 1 , Masato Nakamura 2 , Toshiya Muramatsu 3 , Hisayuki Okada 4 , Masahiko Ochiai 5 , Satoru Suwa 6 , Yutaka Matsuyama 7 , Shinsuke Nanto 8 1 Kokura Memorial Hospital, Kitakyushu, Japan, 2 Toho University Ohashi Medical Center, Tokyo, Japan, 3 Saiseikai Yokohama-city Eastern Hospital, Yokohama, Japan, 4 Seirei Hamamatsu General Hospital, Hamamatsu, Japan, 5 Showa University Northern Yokohama Hospital, Yokohama, Japan, 6 Juntendo University Shizuoka Hospital, Izunokuni, Japan, 7 The University of Tokyo, Tokyo, Japan, 8 Osaka University, Suita, Hyogo Background: Pioglitazone is widely used for glycemic control in patients with type-2 diabetes mellitus (DM), and is associated with a lower risk of cardiovascular events according to a meta-analysis of randomized trials. To evaluate the effect of pioglitazone on ischemic cardiovascular events in Japanese patients with DM and coronary artery disease, after drug-eluting stents (DESs) implantation, the 12-month data from the Japan-Drug Eluting Stents Evaluation; a Randomized Trial (J-DESsERT) was analyzed. Methods: In this prospective, multicenter trial, 3,533 patients were randomized 1:1 to undergo coronary stenting with Sirolimus-eluting stents or Paclitaxel-eluting stents. Lesion lengths were 46 mm, with vessel diameters from !2.5 mm to 3.75 mm. Randomization was stratified based on the presence or absence of DM. Definitions for allocation into the DM group at the time of this trial were: 1. Previous DM diagnosis; 2. Currently on diabetic medication (oral hypoglycemic drugs or insulin injections); 3. HbA1c (Japan diabetes society [JDS]) ! 6.5% within 30 days before the procedure. Patients who met one or more of the above criteria were allocated to the DM group. A total of 1,705 patients (48%) with DM were analyzed from the J-DESsERT trial. Results: Target vessel revascularization (TVR) is defined as any ischemia-driven repeat percutaneous coronary intervention (PCI), target vessel bypass surgery, all death, myocardial infarction (Q wave and non-Q wave), and cerebrovascular accident (stroke, transient ischemic attack). Including TVR, major adverse cardiac cerebrovascular events (MACCE) occurred in only 22 of 357 patients (6.33%) receiving pioglitazone at 12 months. Conversely, substantially more MACCE events occurred in the group not receiving the pioglitazone, 152 of 1,348 patients (11.6%, p¼<0.01). Conclusions: Pioglitazone is associated with a significantly lower MACCE rate at both 8 and 12 months, in Japanese patients with DM, post-DES implantation. www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM Results: There were no significant differences in baseline characteristics except angulated lesion (1st DES vs. 2nd DES: 12.3% vs. 29.2%, p < 0.001), burr-to-artery ratio (0.62 vs. 0.59, p < 0.001), and IVUS use (42.8% vs. 81.7%, p < 0.001). In all patients, no significant differences were observed between 2 groups in the restenosis and TLR rates (21.2 vs. 14.2%, p ¼ 0.12 and 17.1% vs. 11.7%, p ¼ 0.22, respectively). However, the restenosis and TLR rates of 2nd DES were significantly lower than those rates of 1st DES in non-HD patients (19.0% vs. 7.9%, p ¼ 0.015 and 13.9% vs. 5.6%, p ¼ 0.047, respectively). In contrast, those rates were similar between 2 groups in HD patients (30.2 vs. 32.3%, p ¼ 1.0 and 30.2% vs. 29.0%, p ¼ 1.0, respectively). Background: Differences in enrollment criteria and protocol requirements are thought to affect patient representation and outcomes from premarket and postmarket surveillance (PMS). We assessed differences between premarket vs. PMS trials assessing implantation of the Endeavor-zotarolimus eluting stent (E-ZES). Methods: We analyzed data from 2132 and 4357 E-ZES treated subjects (ENDEAVOR premarket and PROTECT PMS trials, respectively). We analyzed differences in 3-year outcomes and adjusted them for differences in baseline characteristics. Results: The two groups differed significantly in baseline characteristics. However, the rates of 3-year major adverse cardiac event (MACE), major adverse cardiac and cerebrovascular event (MACCE) and target vessel failure (TVF), were similar (12.67% vs. 13.88%, p¼0.191; 11.88% vs. 12.68%, p¼0.369; and 13.81% vs. 13.01%, p¼0.419, respectively) . PMS trials had less clinically driven target vessel revascularizations (CD-TVR, p<0.001) and more myocardial infarctions (MI, p¼0.005). Differences emerged at 8 moths and immediately post-procedurally, respectively. After propensity score adjustment, CD-TVR rates no longer differed significantly (HR 0.72, 95% CI 0.51-1.01).
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Conclusions: Premarket and PMS trials assessing E-ZES implantation had similar 3-year composite outcomes. Differences in CD-TVR were attributed to different protocol requirements and in MIs to different outcome definitions. It is yet to be determined if these settings reflect everyday practice.
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One year outcomes of percutaneous coronary intervention with a modern drug-eluting stent in patients with moderate and severe coronary calcification: A pooled analysis from the Nobori-2 and e-Nobori all-comer registries Gert Richardt 1 , Mohamed El-Mawardy 1 , Dmitriy S. Sulimov 1 , Mohamed Abdel-Wahab 1 1 Heart Center, Segeberger Kliniken, Bad Segeberg, Germany Background: Percutaneous coronary intervention (PCI) of moderate and severely calcified lesions has been described as a predictor of worse outcomes when baremetal stents or first-generation drug-eluting stents (DES) have been used. Little is known about the impact of coronary calcification on outcome after PCI with modern DES. Methods: 14,134 patients treated with a biolimus A9-eluting stent with a biodegradable polymer (Nobori, Terumo, Japan) were pooled from 2 all-comer registries (Nobori-2 and e-Nobori). An independent clinical event committee adjudicated all adverse events and an independent corelab analyzed baseline and adverse events' angiograms. Patients were divided into 2 groups based on whether or not PCI was performed on moderate/severely calcified lesions. Target lesion failure (TLF), defined as cardiac death, target vessel-related myocardial infarction and target lesion revascularization, and stent thrombosis were assessed at 1 year. Results: Overall, 4321 patients (30.6%) had moderate/severe coronary calcification. Patients with calcified lesions were older and had a higher rate of diabetes mellitus, hypertension, renal failure, peripheral arterial disease and previous bypass surgery, but less commonly presented with an acute coronary syndrome. Patients with calcified lesions more commonly required multivessel treatment and needed longer stents. Preand post-dilatations were more often performed in the calcified lesions group. Rotational atherectomy or cutting balloons were used in only 5.49%. Preliminary data at 1-year follow-up (currently available in 9,089 patients) revealed low rates of TLF and stent thrombosis, but both were significantly higher in patients with moderate/ severe calcification (TLF in 5.03% vs. 2.83%, p<0.001, stent thrombosis in 0.72% vs. 0.34%, p¼0.03). By multivariate analysis, the presence of moderate/severe calcification was a strong independent predictor of TLF at 1-year (OR1.77, 95%CI 1.23-2.55, p¼0.002). Conclusions: Moderate/severe coronary calcification independently predicts increased rates of TLF at 1-year after PCI with the biolimus A9-eluting Nobori stent, but overall stent performance remains excellent and event rates are surprisingly low. Background: This study was performed to assess angiographic outcomes of newer generation drug-eluting stent (NDES) [everolimus-(EES) or resolute zotarolimuseluting stents (R-ZES)] versus sirolimus-eluting stents (SES) for long or diabetic coronary artery disease. Methods: Patients level data from three randomized trials (Long-DES III, IV and ESSENCE-DIABETES) were pooled to estimate angiographic efficacy of EES or R-ZES versus SES. A total of 1,250 patients underwent EES or R-ZES (NDES group, n¼623) and SES (SES group, n¼627). We evaluated angiographic restenosis after DES implantation at follow-up duration. Results: Follow-up angiography was done in 919 patients (73.5%). In-stent (3.0% vs. 4.4%, p¼0.28) and in-segment restenosis (5.0% vs. 5.2%, p¼0.86) was also statistically not different between NDES vs. SES group. In-segment restenosis was similar between NDES vs. SES group in diabetics (3.9% vs. 6.7%, p¼0.22), > 30 mm long stent implantation patients (6.9% vs. 6.0%, p¼0.64), and 2.5 mm small vessel disease (6.3% vs. 8.7%, p¼0.50). However, lesion length > 40 mm showed significantly higher angiographic restenosis compared to lesion length 40 mm in both stents groups (NDES: 10.2% vs. 3.2 %, p¼0.003: SES: 9.0 % vs. 3.9%, p¼0.03). Conclusions: Newer generation DES showed comparable angiographic outcomes with SES in patients at high risk of restenosis and effectively reduced angiographic restenosis across all high risk lesion subsets, but their angiographic efficacies were attenuated in > 40 mm lesion length in both stent groups. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
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